FYLD | $41,000,000 | (Feb 18, 2026)
The Compression Company | $3,400,000 | (Feb 18, 2026)
Helia Care, Inc. | $3,000,000 | (Feb 18, 2026)
Certified by Founder
Lodge
Syremis Therapeutics
start up
- 19/12/2025
- Series A
- $165,000,000
Syremis Therapeutics is a clinical-stage biopharmaceutical company developing novel medicines to make a profound impact on the treatment of mental health. The company’s neuropsychiatric pipeline is rooted in emerging and clinically validated mechanisms, including muscarinic M1/M4 agonism and next-generation NMDA antagonism.
- Industry Biotechnology Research
- Website https://syremis.com/
- LinkedIn https://www.linkedin.com/company/syremis-therapeutics/
Related People
Elisabeth KoganFounder
Israel -
ND
CEO and Co-founder of Syremis Therapeutics, a Biotech company developing novel therapies for neuropsychiatric conditions.
Experienced Pharma executive with a successful track record of delivering innovation and growth in the pharmaceutical industry.
Passionate about bringing new solutions to patients to reduce suffering and improve quality of life.
Dataro | $14,280,000 | (Feb 18, 2026)
Daffodil Health Corp | $16,300,000 | (Feb 18, 2026)
Sphinx(US) | $7,100,000 | (Feb 18, 2026)
Autosana (YC S25) | $3,200,000 | (Feb 18, 2026)
Tangible | $4,300,000 | (Feb 18, 2026)
Certivo | $4,000,000 | (Feb 18, 2026)
GelMEDIX | $13,000,000 | (Feb 18, 2026)
QuadSci.ai | $8,000,000 | (Feb 18, 2026)
Breaker | $6,000,000 | (Feb 18, 2026)
Bland Company | $2,670,000 | (Feb 18, 2026)